Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma · Ann Arbor Stage III Marginal Zone Lymphoma · Ann Arbor Stage IV Follicular Lymphoma · Ann Arbor Stage IV Marginal Zone Lymphoma · Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Ajay Gopal)
Study leads
Ajay Gopal
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium